市場調査レポート
商品コード
1125990
エスケタミンDPI:新薬の考察と市場予測 (2032年)Esketamine DPI Emerging Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
エスケタミンDPI:新薬の考察と市場予測 (2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
エスケタミンDPI (乾燥粉末吸入器) はケタミン製剤であり、NMDA拮抗薬として作用します。ケタミンは麻酔薬として主に使用されていますが、その抗うつ作用は最近確立されました。エスケタミンは、S-エナンチオマーという形で、R-エナンチオマーに比べて薬理的に3~4倍強力です。しかし、経口製剤の場合、初回通過代謝が大きいため、バイオアベイラビリティが制限されます。そこで、エスケタミンの乾燥粉末吸入剤が開発され、ディスカス型吸入器を用いて、速やかな作用発現と簡便な投与を両立させることを目指しています。このプロジェクトは、患者がエスケタミンを使用する際に革新的で便利な製剤を開発することを目的としています。
当レポートでは、治療抵抗性うつ病の治療薬の一種であるエスケタミンDPI (乾燥粉末吸入器) の市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2025~2032年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、今後の市場成長の可能性などを調査・考察しております。
"Esketamine DPI Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Esketamine DPI for Treatment Resistant Depression in seven major markets. A detailed picture of the Esketamine DPI for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the Esketamine DPI for Treatment Resistant Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Esketamine DPI market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.
Esketamine DPI (Esketamine dry powder Inhaler) is a ketamine formulation and acts as an NMDA antagonist. The antidepressant activity of ketamine was established recently, even though it is majorly used in anesthesia. Esketamine, as in form S-enantiomer, is pharmacologically 3-4 times more potent than R-enantiomer. However, oral formulations are associated with limited bioavailability due to extensive first-pass metabolism. To avoid this, Celon Pharma is developing Esketamine as a dry powder inhalation in a modified Diskus type inhaler to give both fast onsets of action and ease of administration. The project aims to develop an innovative and convenient formulation for patients to use Esketamine.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Esketamine DPI Analytical Perspective by DelveInsight
This report provides a detailed market assessment of Esketamine DPI for Treatment Resistant Depression in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of Esketamine DPI for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions